HOME >> BIOLOGY >> NEWS
ISN's Nexus Hypertension-Kidney debate

The Infinite Gain: three decades on

Delivering the Opening Plenary Lecture, John E. Hall, Guyton Professor, Chairman of Physiology and Biophysics and Director of the Center of Excellence in Cardiovascular -Renal Research (University of Mississippi Medical Center), will present on Renal-Pressure Natriuresis - An Infinite Gain Feedback Mechanism fo Long-Term Blood Pressure Regulation"

The Nexus Plenaries to follow will aim to map the relevance of Guyton's pioneering work in both present and future contexts, spanning a wide range of timely and related topics:

Genomics: Hap Map Project (Aravinda Chakravarti, USA), Proteomics of Renal Exosomes (Mark Knepper, USA), Epidemiology: the Developmental Origins of Adult Disease (David JP Barker, UK), and Circadian control of genes, cells, and organs (Ueli Schibler, Switzerland).

Biomarkers, regultators and risk factors

In alignment with the unique Nexus format, the core program will incorporate three sessions dedicated to both the bench and the 'bedside' levels. Promoting a highly multidisciplnary approach, Hypertension and the Kidney will offer it series of three parallel sessions to deliver the cutting edge basic and clinical discovery aimed at researchers, physicians and clnicians respectively. Mirrored at both levels, the Baisc Science and Clinical Sessions will offer in-depth, rigorous updates on and around RAAS and Cardiovascular Risk, Proteinuria and Hypertension and Diuretics Revisited.

The translational sessions: the jewel in the Nexus crown

The three Translational Sessions - the key and final phase in closing the bench to bedside gap - are naturally offered to all participants. Set to signpost future directions and concrete solutions in research, patient treatment and care - the ultimate step toward addressing real day to day clinical challenges. These sessions will tackle: Guyton's Concept in 2007, Salt-Regulation Effec
'"/>

Contact: Amanda Wren
amanda.wren@isn-online.org
32-473-938-672
International Society of Nephrology
10-May-2007


Page: 1 2

Related biology news :

1. Prize winners announced at ISNs World Congress of Nephrology
2. Research ends debate over benefits of butterfly defenses
3. Lawyers and ethicists debate ashley treatment in open forum
4. Center for Science Writings debate: Redesigning Humanity, March 21
5. Scientists debate the neurobiological underpinnings of amnesia
6. Genome archaeology illuminates the genetic engineering debate
7. Math and fossils resolve a debate on dinosaur metabolism
8. Physics and biology team up to tackle protein folding debate
9. Researchers say environmental pollution is important piece of social justice debate
10. Different but equal: Settling the dosage compensation debate
11. Study continues the debate on the nature of bisexual men

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ISN Nexus Hypertension Kidney debate

(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
(Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
(Date:12/17/2014)... (PRWEB) December 17, 2014 Xeno ... Excellence following its most recent COLA inspection. Xeno ... COLA, a national healthcare accreditation organization. Accreditation is ... of quality in day-to-day operations, demonstrate continued accuracy ... a rigorous on-site laboratory survey. , ...
(Date:12/17/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... the next step in its expanded strategy to rebuild ... the naming of current Chief Operating Officer, Valerie ... current Chairman of the Board and CEO James ... changes are effective January 1, 2015. "Jim ...
(Date:12/17/2014)... SAN FRANCISCO, Calif. , Dec. 17, 2014 ... results of a Phase 2 study evaluating the ... the treatment of patients with severe, chronic itch ... current standard of care, including topical steroids and ... was percent change in Visual Analog Scale (VAS) ...
(Date:12/15/2014)... TIKVAH, Israel , Dec. 15, 2014 ... ), a leading developer of adult stem cell technologies ... Cell Therapeutics Ltd. was awarded a grant of approximately ... of the Chief Scientist (OCS).  This is the eighth ... support from the Office of the Chief Scientist, which ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
Cached News: